Novel Nanofluidic IgE Assay versus a Reference Method: A Real-World Comparison

Area of Science:

• Allergy Diagnostics
• Immunology
• Nanofluidic Technology

Background:

• Accurate specific immunoglobulin E (IgE) determination is crucial for diagnosing allergic diseases.
• Current IgE immunoassays often have lengthy turnaround times, creating a clinical need for faster methods.
• Nanofluidic technology offers potential for rapid, point-of-care allergy diagnostics.

Purpose of the Study:

• To compare the diagnostic agreement of a novel nanofluidic IgE assay (abioSCOPE®) against a standard laboratory reference method (Phadia Laboratory System®).
• To evaluate the utility of the nanofluidic assay in a real-world clinical setting for allergy diagnosis.

Main Methods:

• Sera from 105 patients were analyzed for five respiratory allergens using both the nanofluidic assay and the reference method in a blinded manner.
• Patient records, including history and skin prick tests, were reviewed by four independent experts to establish final diagnoses.
• Agreement was assessed by comparing results from the nanofluidic assay and the reference method against expert-determined diagnoses.

Main Results:

• The nanofluidic IgE assay demonstrated an 81% analytic agreement with the reference method across the tested allergen panel (range: 77-89%).
• The overall agreement in clinical diagnosis decisions, guided by the nanofluidic assay compared to the reference method, reached 94.6%.

Conclusions:

• The nanofluidic IgE assay is a valuable tool for allergy experts, enabling point-of-care identification of patient sensitization patterns.
• This assay supports routine IgE diagnostic workups, integrating clinical history, skin prick tests, and IgE measurements for efficient allergy diagnosis.